LJUBLJANA (Slovenia), May 23 (SeeNews) – Slovenian drug maker Krka [LJE:KRKG] reported on Wednesday a consolidated net profit of 49.4 million euro ($57.9 million) in the first quarter, up 16% on the year.
Consolidated revenue increased 5.4% year-on-year to 338.3 million euro in the three months through March, Krka said in a bourse filing.
Krka's region East Europe reached the highest sales figure in the group, of 106.2 million euro or 31.4% of total group sales. Sales in East Europe rose 4% on the year.
The next largest region in terms of sales was Central Europe, where sales revenues increased 6% to 81.2 million euro, or 24.0% of total sales.
Region West Europe followed, generating sales of 74.0 million euro, or a 21.9% share, and showing an increase of 3% on the year.
Sales in South-East Europe expanded 14% to 44.2 million euro (13.1%), and in Overseas Markets they edged up 1.0% to 11.0 million euro (3.2%).
Sales in Slovenia increased to 21.7 million euro, up 3% on the year, or 6.4% of total Krka Group sales.
Krka's consolidated EBITDA rose to 90.4 million euro at the end of March, from 69.5 million euro a year earlier, while its EBIT jumped 51.1% to 61.9 million euro.
The Krka Group allocated 19.3 million euro to investments in the first quarter, of that 16.3 million euro to the controlling company and 3.0 million euro to subsidiaries.
Krka targets consolidated sales of products and services of 1.3 billion euro at the end of 2018, with sales outside of Slovenia expected to contribute 93% of the total. A profit of 153 million euro is also foreseen.
($=0.853553 euro)